Why the Medical Developments share price charged higher in October

Find out why the Medical Developments International Ltd (ASX: MVP) share price charged 17.7% higher as one of the October ASX winners.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price was one of the big gainers on the ASX last month.

The Aussie medical devices group had a huge month amid announcing a new CSIRO deal and several strong Penthrox updates.

a woman

Why did the Medical Developments share price charge higher?

The Medical Developments share price charged 17.7% higher to $5.85 per share by month-end. The big gains came in mid-October as the company updated the market on its Penthrox product.

Penthrox is an analgesic used by GPs, military forces and similar for emergency pain relief. It's commonly known as the "green whistle" due to the appearance of its hand-held inhaler.

The biggest boost for the Medical Developments share price came on 22 October after a key product update. The company's shares charged higher after Medical Developments reported strong Penthrox results from its European studies.

Just a day later on October 23, the Aussie company launched its signature product in Italy – the latest in a string of milestones.

This also triggered a US$2 million (A$2.9 million) payment from development partner Mundipharma which is expected in 2020.

In late October the company also signed a new Manufacturing Development Project with the CSIRO after 18 years of partnership. Medical Developments will invest up to $5 million over 5 years to develop new manufacturing technologies for pharmaceutical products.

Is November the time to buy?

The Medical Developments share price has outperformed the ASX 200 so far in 2019 after surging 39.44% higher.

The big red flag for me is just how expensive the company's shares are for what you're getting back in earnings.

The Medical Developments price-to-earnings (P/E) ratio is an astonishing 371x earnings, although these metrics can be flawed for growth companies.

Medical Developments has seen solid growth for the last 5 years as its shares have surged 371.43% to $5.94 per share.

However, I think I'd prefer to invest in a blue-chip name like CSL Ltd (ASX: CSL) given where we're at in the cycle right now.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man rests his chin in his hands, pondering what is the answer?
Opinions

Is that the end of the ASX share market crash?

The stock market looks like it has started to recover.

Read more »

Frustrated man at computer desk.
Share Market News

5 most traded ASX 200 shares since the war began

Only one of them is an energy stock.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Opinions

3 reasons to buy NAB shares today

Here's why I think the ASX bank stock is still a buy.

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

Up 222% in a year, why this ASX energy share is forecast to more than double your money again

A leading broker forecasts more outsized gains to come from this rocketing ASX energy share. But why?

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Broker Notes

3 massively popular ASX 200 shares experts say to sell (inc. CBA)

Let's see why they are bearish on these names this week.

Read more »

Two workers working with a large copper coil in a factory.
Broker Notes

Should you buy this $8 billion ASX 200 copper stock amid surging global demand?

A leading analyst drills into the outlook for this $8 billion ASX copper miner.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why BHP, EchoIQ, Life360, and Qantas shares are racing higher today

These shares are having a solid session on Tuesday. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why DroneShield, Guzman Y Gomez, IAG, and Myer shares are falling today

These shares are out of form on Tuesday. But why?

Read more »